AUSTIN - Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019.
Highlights include: Molecular Diagnostics revenue of approximately $65 million, up over 100% vs. Q2 2019
Sample-to-answer MDx revenue of approximately $30 million, up nearly 65% vs. Q2 2019
Non-automated MDx assay revenue of approximately $35 million, up nearly 150% vs. Q2 2019
Automated MDx assay revenue of approximately $26 million, up more than 55% vs. Q2 2019
170 sold or contracted sample-to-answer systems, the majority of which were ARIES Systems
Strong demand driven by pandemic-related sales across all Respiratory/COV-19 products
Licensed Technologies Group revenue of approximately $35 million, down 5% vs. Q2 2019
Placed approximately 210 xMAP systems
Partially affected by slowdown in research market
Flow Cytometry revenue of more than $7 million, down over 45% vs. Q2 2019
Up sequentially by approximately 10%
Continues to be significantly affected by slowdown in academic research
Had an additional $2 million of confirmed orders that were not able to be installed due to the COVID-19 pandemic
'We finished the quarter with record revenue of between $109 and $110 million,' said Nachum 'Homi' Shamir, President and CEO of Luminex. 'With the expected EUA clearance of our IgG serology assay, we will have expanded the breadth of our portfolio and believe that we are well positioned to continue to play a pivotal role in combating the COVID-19 pandemic. In addition, the remainder of our business continues to be healthy, and with xMAP INTELLIFLEX Systems now in our Partners' hands, we are positioned to further strengthen our partnership business with this state-of-the-art platform.'
The full financial results for the quarter, and any changes to 2020 guidance and/or provision thereof, will be discussed on our second quarter earnings call, currently scheduled for August 3, 2020.
ABOUT LUMINEX CORPORATION
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience.
Contact:
Carla Stanaford
Tel: 937-469-2120
Email: cstanaford@luminexcorp.com
LUMINEX CORPORATION 
